Livio Blasi

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Maria Carmela Piccirillo, Paolo A. Ascierto, Carlo Salvarani et al. · Journal of Translational Medicine · 2020 · 112 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey

Alice Indini, C. Aschele, Luigi Cavanna et al. · European Journal of Cancer · 2020 · 110 citations · Full text

Health Professions, Infectious Diseases, Oncology +12

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients

Marina Chiara Garassino, Alain Gelibter, Francesco Grossi et al. · Journal of Thoracic Oncology · 2018 · 85 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients

Sebastiano Mercadante, Paolo Marchetti, Arturo Cuomo et al. · Cancers · 2018 · 61 citations · Full text

Medicine, Oncology, Pharmacotherapy +15